Blood Testing Market Size, Share | Global Forecast [2033]

Blood Testing Market Overview

Global blood testing market size is anticipated to be worth USD 488.41 million in 2024, projected to reach USD 581.2 million by 2033 at a 1.9% CAGR.

The blood testing market is a critical component of global healthcare systems, supporting early diagnosis, disease monitoring, and treatment planning. In 2024, over 2 billion blood tests were conducted globally, indicating the extensive reliance on these diagnostics for conditions such as diabetes, cardiovascular disorders, infections, and cancers. Blood tests remain the most utilized diagnostic tool in clinical settings, accounting for approximately 70% of all medical decisions.

Technological advancements such as high-sensitivity immunoassays, rapid point-of-care testing (POCT), and automated hematology analyzers have transformed the market. In 2023, point-of-care blood testing represented 30% of all diagnostics performed outside hospital settings. Moreover, home blood testing kits witnessed a 40% increase in consumer use between 2022 and 2024 due to increased telemedicine adoption.

The demand for lipid panel testing, glucose monitoring, and thyroid-stimulating hormone (TSH) analysis continues to grow. For instance, lipid profile tests were ordered more than 400 million times globally in 2023. The rise in lifestyle-related diseases, such as obesity and diabetes, is increasing the frequency of A1C and glucose tests, with over 500 million tests conducted in 2024 alone. This surge in usage is pushing laboratories and diagnostics companies to expand capacities, digitalize operations, and develop innovative blood testing solutions.

Key Findings

Top Driver Reason: Rising global prevalence of chronic diseases like diabetes and cardiovascular disorders is driving demand for regular blood testing.

Top Country/Region: North America leads the market with more than 1.1 billion blood tests performed annually, driven by high healthcare expenditure and early diagnostic practices.

Top Segment: Glucose testing is the dominant test type, accounting for over 20% of all global blood test volumes in 2024.

Blood Testing Market Trends

The blood testing market is undergoing rapid transformation driven by rising health awareness, digital healthcare integration, and point-of-care advancements. In 2024, more than 35% of total blood tests globally were facilitated through digital health platforms and remote diagnostics. The demand for decentralized testing has surged, with portable and smartphone-connected blood testing kits gaining traction.

One of the strongest trends in the market is the expansion of point-of-care testing (POCT). The POCT segment experienced a 50% increase in volume from 2022 to 2024, particularly in rural and home settings. POCT glucose meters, hemoglobin analyzers, and cholesterol monitors have been widely adopted, with over 400 million POCT glucose tests performed worldwide in 2024.

Personalized medicine has also influenced market dynamics, with pharmacogenetic blood tests becoming routine in treatment planning. In 2023, over 60 million pharmacogenetic tests were conducted, up from 42 million in 2021, signaling strong momentum in this niche.

Liquid biopsy, a minimally invasive blood test technology for detecting cancer-related biomarkers, gained momentum with more than 20 commercial test kits launched globally between 2023 and 2024. The technology is especially popular in oncology diagnostics, with nearly 1 million liquid biopsies conducted in the United States alone in 2024.

Additionally, digital pathology integration into blood diagnostics has advanced. In 2023, approximately 1,200 diagnostic labs across Europe upgraded to AI-enhanced blood image analysis systems. These systems enabled faster and more accurate readings, reducing test turnaround time by 35% in clinical settings.

Blood Testing Market Dynamics

DRIVER

Rising demand for chronic disease diagnosis and management

Chronic diseases such as diabetes, cardiovascular disorders, kidney disease, and thyroid dysfunction affect over 1.4 billion people globally. As of 2024, there are over 540 million people living with diabetes, leading to an annual demand of more than 600 million glucose and A1C blood tests. Cardiovascular diseases, responsible for over 18 million deaths each year, require constant monitoring via lipid panel tests, CRP assays, and enzyme markers like ALT and AST. The increasing elderly population—projected to surpass 1.5 billion by 2030—is fueling routine screenings and blood-based diagnostics, especially in North America, Europe, and Asia. Preventive testing, early diagnosis, and ongoing disease management protocols are pushing demand for advanced blood testing systems both in hospital and home-care environments.

RESTRAINT

Limited access to advanced diagnostics in low-resource regions

While high-income countries benefit from sophisticated diagnostic infrastructure, low- and middle-income countries (LMICs) face limited access to blood testing technology. Over 40% of diagnostic laboratories in Sub-Saharan Africa and Southeast Asia lack automated analyzers or standardized protocols. In 2024, only 30% of rural health centers in these regions offered routine blood testing services. Moreover, the availability of high-precision immunoassays and AI-based diagnostics is largely restricted to urban hospitals. Additionally, high test costs remain a barrier—A1C and lipid profile tests cost up to $12–$15 in certain regions, unaffordable to large segments of the population. Inconsistent power supply, lack of refrigeration, and shortage of trained lab personnel further restrain market penetration in developing economies.

OPPORTUNITY

Integration of blood testing with digital health ecosystems

The growing adoption of digital healthcare platforms, telemedicine, and remote monitoring is creating significant opportunities for blood testing market players. In 2024, over 50 million blood tests were integrated into cloud-based patient monitoring systems across North America and Western Europe. Smartphone-compatible glucose meters, digital thyroid test kits, and AI-powered analyzers are gaining market share. These tools offer real-time tracking of biomarkers and seamless data transmission to physicians. Over 3,000 hospitals globally have adopted electronic diagnostic records to connect lab results with treatment systems. This digital transformation is creating avenues for companies to offer subscription-based blood testing, remote lab sample collection, and home diagnostics solutions for routine and chronic care management.

CHALLENGE

Rising costs of innovation and regulatory compliance

Innovation in the blood testing market requires high R&D investment, with molecular and genetic-level diagnostics posing significant regulatory hurdles. Bringing a new blood test to market can take up to 5 years and cost over $100 million due to the need for clinical trials, validations, and approvals. Regulatory authorities such as the FDA and EMA have tightened requirements on analytical sensitivity, specificity, and safety standards. In 2024, over 80 blood testing devices failed to receive regulatory clearance in their first submissions. Furthermore, market players must constantly upgrade technology to meet emerging health threats such as pandemics, adding pressure to control development costs. Smaller players often struggle with these barriers, leading to consolidation and reduced competition in some regional markets.

Blood Testing Market Segmentation

The blood testing market is segmented by type and application, enabling targeted diagnostics, optimized resource allocation, and efficient medical outcomes. Segmentation by type includes a wide range of tests such as glucose, lipid, BUN, A1C, CRP, vitamin D, ALT, AST, and thyroid stimulating hormone (TSH). By application, the market is categorized into hospitals, clinics and diagnostic centers, and others (including homecare and research institutions).

By Type

Glucose: Glucose testing is the most frequently performed blood test globally. In 2024, over 600 million glucose tests were conducted to monitor diabetes and assess blood sugar levels during emergency evaluations. Point-of-care glucose meters are used in over 70% of diabetes cases worldwide. With over 540 million people living with diabetes globally, the demand for both fasting blood glucose and random glucose tests continues to grow. In hospital ICUs and emergency departments, glucose testing is used for real-time assessment, while at-home kits represent 45% of all glucose testing volume.
Lipid: Lipid panel testing evaluates cholesterol levels, triglycerides, HDL, and LDL concentrations, primarily for cardiovascular risk assessment. In 2024, more than 400 million lipid profile tests were performed globally. The American Heart Association recommends lipid screening every 4–6 years for adults, driving mass adoption. Lipid tests are conducted as part of annual health screenings in corporate wellness programs and insurance-linked diagnostics, with 120 million tests administered in employer-sponsored packages alone.
BUN (Blood Urea Nitrogen): BUN testing is crucial for assessing kidney function and detecting dehydration or liver dysfunction. In 2023, over 90 million BUN tests were conducted globally. Patients with hypertension, diabetes, and chronic kidney disease undergo BUN and creatinine testing as standard procedures. In North America, BUN tests are ordered in nearly 60% of hospital admissions involving renal evaluation. Combined BUN-creatinine panels are frequently included in comprehensive metabolic panels.
A1C (Glycated Hemoglobin): The A1C test provides an average blood glucose level over the past 2–3 months and is essential for diabetes monitoring. Over 300 million A1C tests were conducted in 2024 globally, with 150 million tests performed in primary care settings. A1C levels above 6.5% are used to diagnose diabetes, as per WHO guidelines. Health insurers and wellness programs routinely include A1C screening, especially in corporate and urban health checkups.
CRP (C-Reactive Protein): CRP testing measures inflammation and is used in diagnosing infections, autoimmune diseases, and cardiovascular conditions. Over 130 million CRP tests were conducted globally in 2024. These tests are especially common in COVID-19 diagnostics and respiratory disease evaluations. In Europe, CRP testing is mandated before antibiotic prescriptions in several countries to prevent misuse of antibiotics.
Vitamin D: Vitamin D blood testing has seen a dramatic rise in demand, with 210 million tests performed globally in 2024. Urban lifestyle changes, limited sunlight exposure, and awareness campaigns have led to increased screenings. In India alone, over 40 million vitamin D tests were administered, mainly in private diagnostic centers. These tests are also used in managing osteoporosis and autoimmune diseases.
ALT (Alanine Aminotransferase): ALT testing is conducted to assess liver function, especially in hepatitis, fatty liver, and drug-induced toxicity. Over 95 million ALT tests were recorded globally in 2024. ALT values are monitored in clinical trials involving liver-targeting drugs. In Asia-Pacific, rising liver-related conditions have increased ALT screening rates by 20% since 2022.
AST (Aspartate Aminotransferase): Similar to ALT, AST tests are used to diagnose liver, heart, and muscle disorders. In 2024, around 88 million AST tests were conducted globally. These are frequently paired with ALT in liver panels. Hospitals in Latin America and Southeast Asia have included AST in standard liver evaluations due to rising non-alcoholic fatty liver disease.
Thyroid Stimulating Hormone (TSH): TSH testing is critical in diagnosing hypothyroidism and hyperthyroidism. With an increasing prevalence of thyroid disorders, over 240 million TSH tests were performed in 2024. Women account for 70% of all TSH testing due to higher susceptibility to thyroid dysfunction. In countries like the U.S. and Japan, TSH is part of maternal health and fertility evaluations.

By Application

Hospitals: Hospitals accounted for over 55% of all blood testing volume in 2024. Tertiary care hospitals conduct high-complexity testing including liquid biopsies, immunoassays, and blood cultures. ICUs and surgical wards rely on real-time blood diagnostics, with large hospitals performing over 500 different blood test variants daily. Globally, over 1.2 billion blood tests were performed in hospital settings in 2024.
Clinics and Diagnostic Centers: Standalone clinics and diagnostics labs handle a significant share of routine testing. In 2024, over 900 million tests were performed by private diagnostics chains. These centers specialize in high-throughput automated blood testing using immunoassay systems and autoanalyzers. Urban clinics perform an average of 350 tests daily, primarily glucose, lipid, TSH, and CRP.
Others (Homecare, Research Institutes): Home blood testing gained popularity during the pandemic and has remained in demand for chronic disease management. In 2024, over 150 million tests were self-administered using home test kits. Additionally, research institutions conducted over 50 million blood tests in 2024 for clinical trials, biomarker discovery, and epidemiological studies. Startups offering subscription-based home testing solutions are expanding rapidly.

Blood Testing Market Regional Outlook

The global blood testing market demonstrates a highly diverse regional performance shaped by healthcare infrastructure, regulatory standards, disease prevalence, and testing affordability. North America dominates in terms of test volume, while Asia-Pacific leads in growth potential due to expanding diagnostic networks. Europe maintains a strong position with regulated diagnostic frameworks and widespread preventive testing initiatives, whereas the Middle East & Africa shows gradual expansion driven by healthcare investments and rising urban populations.

North America

North America remains the leading region in the blood testing market with over 1.1 billion tests conducted in 2024. The United States alone accounted for 950 million blood tests, driven by routine check-ups, chronic disease monitoring, and advanced cancer diagnostics. The region is a hub for technological innovation, with over 400 hospitals equipped with AI-based diagnostic analyzers and over 50 million home testing kits sold in 2024. Canada's preventive health programs contributed to 120 million routine blood screenings in 2024. The region’s strong insurance coverage, high patient awareness, and growing demand for telemedicine have further accelerated the market.

Europe

Europe performed over 900 million blood tests in 2024, supported by universal healthcare systems and mandatory diagnostic protocols. Countries like Germany, France, and the UK collectively accounted for over 70% of this volume. Preventive testing, especially for cardiovascular and thyroid conditions, is embedded in public health policy. In 2023, more than 35% of all diagnostic tests in Europe were blood-based. Digital pathology labs are growing, with over 1,200 labs across the region using machine-learning tools for blood diagnostics. CRP and lipid tests are among the most prescribed diagnostics, with 250 million lipid tests administered across EU nations in 2024.

Asia-Pacific

Asia-Pacific witnessed more than 1 billion blood tests in 2024, propelled by population density and rising awareness of lifestyle diseases. India and China led the region with over 300 million and 400 million tests, respectively. Japan and South Korea continue to pioneer technological advancements, with more than 5,000 clinics offering digital blood testing services. Urban expansion and corporate wellness programs have triggered high uptake of glucose, A1C, and vitamin D tests. Government health schemes in China and India sponsored over 120 million free blood screenings in 2024, primarily targeting rural areas and low-income populations.

Middle East & Africa

The Middle East & Africa conducted over 250 million blood tests in 2024. While adoption remains lower than other regions, countries such as Saudi Arabia, UAE, and South Africa have invested heavily in diagnostic infrastructure. Over 300 new diagnostic labs were launched in 2023 across this region. In GCC countries, routine blood panels are often included in employment-based medical assessments. CRP and TSH testing are commonly used in urban hospitals, while glucose and lipid testing are expanding in rural outreach programs. The region still faces challenges in equipment accessibility, with over 40% of clinics lacking full laboratory automation as of 2024.

List of Top Blood Testing Market Companies

Abbott Laboratories
Bio-Rad Laboratories
Hoffmann-La Roche
Siemens Healthineers

Top Two Companies with the Highest Market Share

Abbott Laboratories: Abbott Laboratories remains one of the global leaders in blood testing, offering over 400 diagnostic test variants through its core laboratory and rapid diagnostics divisions. In 2024, Abbott’s diagnostics segment performed over 150 million blood tests globally. Its FreeStyle Libre glucose monitoring system alone was used by more than 5 million diabetics across 50 countries. Abbott’s global presence includes more than 150 diagnostic laboratories and partnerships with over 2,000 healthcare institutions

Hoffmann-La Roche: Roche is another major force in the global blood testing space. As of 2024, Roche's blood-based diagnostics were available in over 100 countries and used in more than 75% of hospitals across Europe. Roche’s cobas® e analyzers conducted over 500 million blood-based immunoassays globally in 2023–2024. The company invested over $1.2 billion in 2024 into expanding molecular and blood-based diagnostic capabilities across Asia and Latin America.

Investment Analysis and Opportunities

The blood testing market is witnessing significant investment activity across diagnostics infrastructure, point-of-care innovation, digital health integration, and biotech collaborations. In 2024, over $15 billion was invested globally in diagnostics research and facility upgrades related to blood-based testing technologies. A substantial portion of this investment came from private equity firms, government-funded health programs, and strategic corporate partnerships aiming to expand accessibility, automation, and data-driven diagnostics.

A key area of investment is automation in laboratory diagnostics. In 2024, over 2,500 laboratories across North America and Europe upgraded to high-throughput immunoassay analyzers and hematology platforms, significantly reducing turnaround times by 30%. This investment trend reflects the need for rapid diagnostics in emergency rooms and outpatient departments, which together processed over 1.5 billion blood tests globally in 2024.

Another focus of investor interest is point-of-care blood testing solutions. Startups and diagnostics manufacturers are receiving strong venture capital backing. In 2023 and 2024, over 50 startups received funding exceeding $500 million collectively for developing portable, AI-powered blood diagnostic kits. These devices are now widely used in rural clinics and home-care setups, with 150 million blood tests administered outside traditional lab environments in 2024.

New Product Development

The blood testing market has witnessed a surge in new product development between 2023 and 2024, focused on innovation, rapid diagnostics, and personalized healthcare solutions. This period marked the introduction of over 100 novel diagnostic products, including advanced analyzers, portable testing kits, multiplex panels, and digital health-integrated tools. These innovations are enabling faster, more accurate, and accessible testing across both clinical and home-care settings.

A major innovation trend has been the development of AI-integrated blood analysis systems. In 2024, more than 500 diagnostic laboratories adopted AI-enabled hematology platforms capable of analyzing over 50 blood parameters within 60 seconds. These systems enhanced diagnostic accuracy by 22% in high-volume testing environments. Companies like Siemens Healthineers and Roche have introduced AI-based image recognition in their blood analyzers for identifying rare blood disorders and early disease markers.

Another breakthrough came with next-generation liquid biopsy kits. In 2023 and 2024, over 20 commercial products were launched, including multi-cancer early detection kits that use blood to identify biomarkers associated with colorectal, pancreatic, and lung cancers. These kits allow diagnosis before symptom onset, with sensitivity rates exceeding 85% in early clinical evaluations. These innovations are being integrated into oncology care pathways across 25 countries.

Five Recent Developments

Abbott Laboratories launched FreeStyle Libre 4 with integrated blood ketone tracking (2024): In 2024, Abbott released the FreeStyle Libre 4 system, enhancing glucose monitoring with real-time ketone tracking from capillary blood samples. The system was adopted by over 1.5 million new users globally within six months of launch, aiding diabetic ketoacidosis (DKA) prevention.
Roche introduced cobas® pulse POCT system in 2023 for decentralized diagnostics: Roche's cobas® pulse, a handheld device capable of performing 10+ blood tests including CRP, glucose, and hemoglobin A1C, was deployed in over 3,000 clinics in Europe and Asia-Pacific by late 2024, reducing point-of-care testing time by 45%.
Bio-Rad launched multiplex autoimmune panel for blood-based early screening (2024): Bio-Rad released a new autoimmune panel that tests for 15 biomarkers using just 3 mL of blood. The product was adopted in over 500 immunology labs by Q1 2024, enabling early detection of lupus, RA, and other autoimmune diseases.
Siemens Healthineers introduced AI-powered Atellica® CI Analyzer (2023): In 2023, Siemens launched the Atellica® CI Analyzer, integrating AI to automate high-volume blood testing with over 120 assays. More than 1,000 hospitals adopted the system by 2024, with diagnostic output increasing by 30%.
Thermo Fisher expanded CRP testing reagent portfolio across Asia (2024): Thermo Fisher introduced new high-sensitivity CRP reagents in 2024 for cardiovascular inflammation screening. The reagents were adopted by over 1,200 laboratories across India, China, and South Korea within the first 8 months.

Report Coverage of Blood Testing Market

This report comprehensively covers the global blood testing market, focusing on diagnostic technologies, test categories, application environments, and evolving regional trends. The scope includes detailed analysis of more than 10 core blood test types, including glucose, lipid, A1C, CRP, BUN, vitamin D, ALT, AST, and TSH—each playing a critical role in chronic disease detection, health monitoring, and emergency diagnostics.

The market coverage encompasses primary settings where blood testing is performed, such as hospitals, standalone clinics, diagnostic centers, homecare services, and research institutions. The report evaluates over 2.5 billion blood tests performed in 2024 alone, breaking them down by type, frequency, and use-case. For instance, glucose and A1C tests accounted for more than 900 million combined tests in the same year, while vitamin D and CRP collectively crossed 340 million test volumes globally.

Key manufacturers are profiled, including market leaders such as Abbott Laboratories, Roche, Bio-Rad, and Siemens Healthineers. The report highlights their latest innovations, strategic collaborations, and technological advancements in automated systems, POCT devices, and digital diagnostics integration. Additionally, it evaluates the impact of product launches, such as Roche's cobas® pulse and Siemens' Atellica® CI Analyzer, on test turnaround time, accuracy, and healthcare access.

Geographic coverage includes detailed analysis of North America, Europe, Asia-Pacific, and the Middle East & Africa. North America led with over 1.1 billion blood tests in 2024, while Asia-Pacific followed closely with more than 1 billion, driven by government health schemes and consumer-driven testing kits. Each region is assessed for laboratory capacity, healthcare penetration, digital transformation, and disease prevalence rates.